Valneva and Pfizer report positive Phase 2 data for Lyme disease vaccine in children

Valneva and Pfizer report positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15: and now plan to include this population in an upcoming Phase 3 trial.